A research group at Charles Surt University (Australia) and others conducted a study to evaluate the effects of BioBran. They published a research paper titled “Evidence-Based Review of BioBran/MGN-3 Arabinoxylan Compound as a Complementary Therapy for Conventional Cancer Treatment”.

This study was published in “Integrative Cancer Therapies 1–14, 2017 ”.